MIRO-CKD — Balcinrenone + dapagliflozin beat dapagliflozin alone on UACR (2025) — Trial Summary
MIRO-CKD — Balcinrenone + dapagliflozin beat dapagliflozin alone on UACR (2025): Multicenter, randomized, double-blind, active-controlled, dose-finding phase 2b trial at 106 sites in 15 countries comparing balcinrenone 15 mg + dapagliflozin 10 mg, balcinrenone 40 mg + dapagliflozin 10 mg, or dapagli
References
- Heerspink HJL, Cardona JF, Jolly S, et al; MIRO-CKD study investigators. Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial. Lancet. 2025;406(10518):2449-2460.